Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 9/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357085 | 0.90 | ADORA1 (0.56) | ADORA1CSNK2A1CSNK2A2CSNK2BGSK3B | |
| SCHEMBL5408086 | 0.83 | ADORA1 (0.85) | ADORA1GSK3BADORA3GSK3A | |
| SCHEMBL5351179 | 0.77 | ADORA1 (0.45) | ADORA1CSNK2A1BRD4 | |
| SCHEMBL5429671 | 0.72 | ADORA1 (0.77) | ADORA1GSK3BADORA3 | |
| SCHEMBL5362434 | 0.72 | ADORA1 (0.77) | ADORA1BRD4ADORA3 | |
| SCHEMBL5355732 | 0.72 | BRD4 (0.52) | BRD4 | |
| SCHEMBL5370881 | 0.69 | BRD4 (0.42) | ADORA1BRD4 | |
| SCHEMBL5356781 | 0.68 | ADORA1 (0.45) | ADORA1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4972494 | 0.68 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BHDAC6 | |
| SCHEMBL10134704 | 0.68 | CSNK2A1 (0.92) | CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202245-B2 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | CYP4B1, CYP3A4, CYP1B1 | ADORA1 12/4885CSNK2A1 845/4885CSNK2A2 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.